COVID-19 vaccine acceptance among pregnant women worldwide: A systematic review and meta-analysis.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
03
2022
accepted:
15
07
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has led to the death of many people worldwide. The World Health Organization (WHO) has declared vaccine resistance as one of the greatest health threats in the world even before the COVID-19 epidemic. The aim of this study was to evaluate the acceptance of COVID-19 vaccine in pregnant women. We performed this systematic review and meta-analysis in accordance with the PRISMA guidelines. We applied the standard search strategy to the PubMed/Medline, Web of Science (ISI), Scopus, Science Direct, Cochrane Library, EMBASE, and EBSCO databases, and the Google Scholar search engine. Heterogeneity between studies was relatively high and therefore meta-analyses were performed based on random effects model with 95% CI using STATA version 16. In 16 articles with a sample size of 19219 pregnant women, the acceptance of COVID-19 vaccine was estimated 53.46% (95%CI: 47.64%-59.24%). Subgroup analysis was performed based on continent (p = 0.796), data collection method (p = 0.450) and meta-regression based on the month of the study (P<0.001), and only meta-regression was significant based on the month of the study. The effect of some variables such as graviad (OR = 1.02 [95%CI: 0.90-1.16]), maternal age was (OR = 1.02 [95%CI: 0.93-1.11]) and history of influenza vaccination (OR = 0.87 [95%CI: 0.71-1.06]) on COVID-19 vaccine acceptance was evaluated, which was not significant. The prevalence of COVID-19 vaccine acceptance in pregnant women was 53.46%, which was much lower than the general COVID-19 vaccination. Therefore, necessary interventions should be taken to increase the acceptance of the vaccine, address safety concerns and educate about it.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has led to the death of many people worldwide. The World Health Organization (WHO) has declared vaccine resistance as one of the greatest health threats in the world even before the COVID-19 epidemic. The aim of this study was to evaluate the acceptance of COVID-19 vaccine in pregnant women.
METHOD
We performed this systematic review and meta-analysis in accordance with the PRISMA guidelines. We applied the standard search strategy to the PubMed/Medline, Web of Science (ISI), Scopus, Science Direct, Cochrane Library, EMBASE, and EBSCO databases, and the Google Scholar search engine. Heterogeneity between studies was relatively high and therefore meta-analyses were performed based on random effects model with 95% CI using STATA version 16.
RESULTS
In 16 articles with a sample size of 19219 pregnant women, the acceptance of COVID-19 vaccine was estimated 53.46% (95%CI: 47.64%-59.24%). Subgroup analysis was performed based on continent (p = 0.796), data collection method (p = 0.450) and meta-regression based on the month of the study (P<0.001), and only meta-regression was significant based on the month of the study. The effect of some variables such as graviad (OR = 1.02 [95%CI: 0.90-1.16]), maternal age was (OR = 1.02 [95%CI: 0.93-1.11]) and history of influenza vaccination (OR = 0.87 [95%CI: 0.71-1.06]) on COVID-19 vaccine acceptance was evaluated, which was not significant.
CONCLUSION
The prevalence of COVID-19 vaccine acceptance in pregnant women was 53.46%, which was much lower than the general COVID-19 vaccination. Therefore, necessary interventions should be taken to increase the acceptance of the vaccine, address safety concerns and educate about it.
Identifiants
pubmed: 36170334
doi: 10.1371/journal.pone.0272273
pii: PONE-D-22-08719
pmc: PMC9518917
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0272273Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Iran J Public Health. 2020 Oct;49(Suppl 1):18-29
pubmed: 34268202
Infect Drug Resist. 2021 Jun 24;14:2361-2367
pubmed: 34194232
Arch Virol. 2018 Feb;163(2):319-330
pubmed: 29063378
J Cell Physiol. 2021 Jan;236(1):49-54
pubmed: 32542735
Med Decis Making. 2005 Nov-Dec;25(6):646-54
pubmed: 16282215
MMWR Morb Mortal Wkly Rep. 2010 Dec 3;59(47):1541-5
pubmed: 21124293
Vaccine. 2016 Jul 25;34(34):3942-9
pubmed: 27317458
Pol J Radiol. 2021 Jan 14;86:e31-e49
pubmed: 33708271
Eur J Epidemiol. 2020 Apr;35(4):325-330
pubmed: 32318915
Vaccine. 2011 Sep 2;29(38):6472-84
pubmed: 21756960
Mol Cell Probes. 2020 Oct;53:101636
pubmed: 32634550
Am J Perinatol. 2022 Jan;39(1):75-83
pubmed: 34598291
Am J Obstet Gynecol MFM. 2021 Jul;3(4):100352
pubmed: 33771762
Nature. 2020 Jun;582(7811):230-233
pubmed: 32499650
Lancet Infect Dis. 2020 Nov;20(11):1217
pubmed: 33038942
Clin Epidemiol Glob Health. 2021 Oct-Dec;12:100899
pubmed: 34746514
Obstet Gynecol. 2020 Aug;136(2):273-282
pubmed: 32555034
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34101621
Int J Environ Res Public Health. 2021 Mar 24;18(7):
pubmed: 33805097
Prev Med. 2021 Sep;150:106694
pubmed: 34171345
J Clin Epidemiol. 2020 Apr;120:94-103
pubmed: 31866469
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
Am J Obstet Gynecol MFM. 2021 Sep;3(5):100399
pubmed: 34020098
Hum Vaccin Immunother. 2018;14(10):2355-2357
pubmed: 29617173
Mol Biol Rep. 2020 Jul;47(7):5365-5376
pubmed: 32601923
Int J Environ Res Public Health. 2021 Feb 18;18(4):
pubmed: 33670821
BMC Public Health. 2021 Apr 26;21(1):804
pubmed: 33902501
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129
pubmed: 33507892
Front Immunol. 2020 Oct 14;11:585354
pubmed: 33163000
Int J Gen Med. 2021 Jun 08;14:2385-2395
pubmed: 34135622
Appl Psychol Health Well Being. 2021 May;13(2):469-484
pubmed: 33634930
BMC Pregnancy Childbirth. 2021 Jan 15;21(1):59
pubmed: 33451292
Vaccine. 2020 Nov 10;38(48):7668-7673
pubmed: 33071002
Reprod Health. 2021 Jan 18;18(1):10
pubmed: 33461593
N Engl J Med. 2020 Dec 3;383(23):2202-2204
pubmed: 32897660
Glob Pediatr Health. 2019 Jul 24;6:2333794X19862949
pubmed: 31384629
Lancet. 1998 Jan 31;351(9099):356-61
pubmed: 9652634
Vaccines (Basel). 2021 May 24;9(6):
pubmed: 34073757
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Int J Gynaecol Obstet. 2021 Aug;154(2):291-296
pubmed: 33872386
Am J Obstet Gynecol MFM. 2021 Sep;3(5):100403
pubmed: 34048965
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Health Aff (Millwood). 2016 Feb;35(2):284-92
pubmed: 26858382
JAMA. 2016 Mar 15;315(11):1149-58
pubmed: 26978210
BMC Pregnancy Childbirth. 2022 Jan 14;22(1):33
pubmed: 35030996
Hum Vaccin Immunother. 2020 Jul 2;16(7):1511-1520
pubmed: 31977285
Health Technol Assess. 2010 Jul;14(34):183-266
pubmed: 20630124
Women Birth. 2022 May;35(3):317-323
pubmed: 34088595
SAGE Open Med. 2021 Aug 19;9:20503121211038454
pubmed: 34434555
Eur J Epidemiol. 2021 Feb;36(2):197-211
pubmed: 33649879
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
Vaccine. 2015 Nov 25;33(47):6420-9
pubmed: 26320417
Hum Vaccin Immunother. 2021 Aug 3;17(8):2378-2388
pubmed: 33989109
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
Vaccine. 2012 Jul 6;30(32):4733-43
pubmed: 22643216
Trop Med Int Health. 2021 Oct;26(10):1303-1313
pubmed: 34370375
J Matern Fetal Neonatal Med. 2021 Apr 11;:1-4
pubmed: 33843419
J Pediatr. 2016 Feb;169:305-9
pubmed: 26621045
Syst Rev. 2021 Jan 26;10(1):39
pubmed: 33499930
PLoS One. 2020 Jul 9;15(7):e0234827
pubmed: 32645112
Hum Vaccin Immunother. 2021 Oct 3;17(10):3371-3376
pubmed: 34009096
Vaccines (Basel). 2020 Jun 17;8(2):
pubmed: 32560340